Drugs.com Clinical Trial ResultsOriginal article
Lundbeck Receives FDA Fast Track Designation for Lu AH69593, an Investigational Orexin 2 Receptor Agonist for Narcolepsy
RegulatoryLu AH69593Positive
AI Analysis
Summary
Lundbeck announced that the FDA granted Fast Track designation to Lu AH69593, an investigational oral orexin 2 receptor agonist being developed for narcolepsy treatment.
Outcome Details
Fast Track designation granted
Importance:6/10
Sentiment:
0.70
FDAFast Track DesignationOrexin 2 Receptor AgonistNarcolepsyRegulatory
Related Companies
Read the original article
Published by Drugs.com Clinical Trial Results on July 23, 2026 7:07 PM